{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"42.8","value":"14.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"EBV positive related gastric cancer"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.4","upperLimit":"30.2","value":"11.5"},{"groupId":"OG001","lowerLimit":"17.6","upperLimit":"47.1","value":"31.0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"36.9","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"HPV positive SCCHN"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"16.4","upperLimit":"57.3","value":"34.8"},{"groupId":"OG002","lowerLimit":"8.2","upperLimit":"47.2","value":"23.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Other anogenital HPV associated cancers"},{"categories":[{"measurements":[{"groupId":"OG004","lowerLimit":"0.4","upperLimit":"64.1","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"title":"SCCHN I-O naive"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.1","upperLimit":"51.2","value":"26.3"},{"groupId":"OG001","lowerLimit":"18.2","upperLimit":"46.6","value":"31.1"},{"groupId":"OG002","lowerLimit":"25.7","upperLimit":"55.7","value":"40.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Cervical, Randomized"},{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"31.0","upperLimit":"49.9","value":"40.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"112"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Cervical, Pooled"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"71.6","value":"20.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Vaginal/Vulvar"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.7","upperLimit":"78.9","value":"60.0"},{"groupId":"OG001","lowerLimit":"42.1","upperLimit":"73.0","value":"58.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"MCC"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.7","upperLimit":"37.4","value":"16.7"},{"groupId":"OG001","lowerLimit":"15.7","upperLimit":"44.6","value":"28.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"NPC"}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"195"},{"groupId":"OG002","value":"133"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) using RECIST 1.1 criteria. An ORR in excess of 10% will be considered of clinical interest, and an ORR of 25% or greater will be considered of strong clinical interest.\n\nComplete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n\nPartial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.\n\nParticipants with the following diseases will be assessed:\n\n1. EBV positive related gastric cancer;\n2. HPV positive SCCHN;\n3. Other anogenital HPV associated cancers;\n4. GYN (Cervical, Vaginal, Vulvar) carcinoma;\n5. Merkel cell carcinoma (MCC);\n6. Nasopharyngeal carcinoma (NPC) Note: \"Cervical, Randomized\" and \"Cervical, Pooled\" are not mutually exclusive categories","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab IV over 30 minutes at 240 mg every 2 weeks for a maximum of 24 months or until disease progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG000","title":"Metastatic Monotherapy"},{"description":"Nivolumab 3 mg/kg IV over 30 minutes every 2 weeks + Ipilimumab 1 mg/kg IV over 30 minutes every 6 weeks for a maximum of 24 months or until disease progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG001","title":"Metastatic Combo A"},{"description":"Nivolumab 1 mg/kg IV over 30 minutes + Ipilimumab 3 mg/kg IV over 30 minutes every 3 weeks for 4 doses followed by Nivolumab 240 mg IV over 30 minutes every 2 weeks for a maximum of 24 months or until disease progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG002","title":"Metastatic Combo B"},{"description":"Nivolumab 240 mg IV over 30 minutes + BMS-986016 (Relatlimab) 80 mg IV over 60 minutes administered every 2 weeks for a maximum of 24 months, or until disease progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG003","title":"Metastatic Combo C"},{"description":"Daratumumab 16 mg/kg IV weekly for the first 8 weeks. Starting at Week 3, Nivolumab 240 mg IV over 30 minutes every 2 weeks. Daratumumab 16 mg/kg every 2 weeks from Weeks 9-24. Starting at Week 25, Nivolumab 480 mg IV flat dose over 30 minutes every 4 weeks; daratumumab 16 mg/kg every 4 weeks for a maximum of 24 months or until progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG004","title":"Metastatic Combo D"}],"paramType":"NUMBER","populationDescription":"All treated participants in the metastatic cohorts","reportingStatus":"POSTED","timeFrame":"From the date of first dose to the date of the initial objectively documented tumor progression or the date of the last tumor assessment prior to subsequent therapy (Up to 83 months)","title":"Metastatic: Investigator-Assessed Objective Response Rate (ORR) Extended Collection","type":"POST_HOC","unitOfMeasure":"Percentage of participants"}